Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cytek Biosciences Inc (CTKB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CTKB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.8% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 502.14M USD | Price to earnings Ratio - | 1Y Target Price 6.9 |
Price to earnings Ratio - | 1Y Target Price 6.9 | ||
Volume (30-day avg) 880106 | Beta 1.42 | 52 Weeks Range 3.88 - 7.63 | Updated Date 04/2/2025 |
52 Weeks Range 3.88 - 7.63 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3% | Operating Margin (TTM) 0.67% |
Management Effectiveness
Return on Assets (TTM) -2.91% | Return on Equity (TTM) -1.53% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 241296725 | Price to Sales(TTM) 2.5 |
Enterprise Value 241296725 | Price to Sales(TTM) 2.5 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA -133.96 | Shares Outstanding 128097000 | Shares Floating 109802511 |
Shares Outstanding 128097000 | Shares Floating 109802511 | ||
Percent Insiders 8.9 | Percent Institutions 61.33 |
Analyst Ratings
Rating 4 | Target Price 8.4 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cytek Biosciences Inc
Company Overview
History and Background
Cytek Biosciences, Inc. was founded in 2006. They initially focused on developing and manufacturing high-performance flow cytometry instruments. Over time, the company has evolved to offer a range of cell analysis solutions, including instruments, reagents, and software.
Core Business Areas
- Instruments: Development, manufacture, and commercialization of cell analysis instruments based on Full Spectrum Profilingu2122 (FSPu2122) technology. These instruments allow for high-resolution, high-content cellular analysis.
- Reagents: Manufacturing and sale of reagents optimized for use with Cytek instruments. This includes a broad portfolio of fluorochrome-conjugated antibodies and other cell staining products.
- Software and Services: Development and support of software solutions for data acquisition, analysis, and visualization. This also includes customer support and training services.
Leadership and Structure
Cytek Biosciences is led by Wenbin Jiang, PhD, as CEO. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance and operations.
Top Products and Market Share
Key Offerings
- Aurora Cytometer: A full spectrum flow cytometer capable of resolving more fluorophores than traditional flow cytometers, allowing for deeper and more complex biological insights. Competing with BD Biosciences' FACSymphony, Beckman Coulter's CytoFLEX, and Thermo Fisher's Attune NxT. Market share is growing but not definitively public. Revenue from Aurora is a major revenue stream for Cytek, but specific revenue number is not public
- Northern Lights Cytometer: A lower-cost, compact full spectrum flow cytometer designed for routine applications and smaller labs. Competitors are similar to Aurora but at a different price point. Market share is growing but not definitively public. Revenue from Northern Lights is a major revenue stream for Cytek, but specific revenue number is not public
- Reagents and Assays: A comprehensive portfolio of reagents and assays designed and optimized for use with Cytek's FSP platform including cFluor reagents, cell staining products, cell separation kits, buffers, and consumables. Competitors include BioLegend, BD Biosciences, Thermo Fisher Scientific. Market share is growing but not definitively public. Revenue from Reagents and Assays is a major revenue stream for Cytek, but specific revenue number is not public.
Market Dynamics
Industry Overview
The cell analysis market is driven by increasing research in immunology, oncology, and drug discovery. Advancements in flow cytometry technology, particularly in spectral flow cytometry, are fueling growth. The market is competitive, with established players and emerging companies vying for market share.
Positioning
Cytek Biosciences is positioned as a leader in spectral flow cytometry. Their FSP technology offers unique advantages in terms of sensitivity, resolution, and flexibility, allowing them to compete effectively with established players.
Total Addressable Market (TAM)
The global flow cytometry market is expected to reach approximately $6.0 billion by 2027. Cytek is positioned to capture a significant portion of this market through its innovative technology and expanding product portfolio.
Upturn SWOT Analysis
Strengths
- Innovative Full Spectrum Profiling (FSP) technology
- High-resolution, high-content cellular analysis capabilities
- Strong customer support and training
- Growing installed base of instruments
- Comprehensive reagent portfolio
Weaknesses
- Relatively smaller size compared to established players
- Reliance on specific technologies
- Potential for supply chain disruptions
- Slower rate of adoption relative to existing flow cytometry users
Opportunities
- Expanding applications in immunotherapy and personalized medicine
- Increasing demand for high-throughput cell analysis
- Partnerships with pharmaceutical and biotechnology companies
- Geographic expansion into emerging markets
- Development of new reagents and assays
Threats
- Competition from established players with broader product portfolios
- Technological advancements by competitors
- Regulatory changes affecting cell analysis
- Economic downturns impacting research funding
- Patent infringement or challenges to intellectual property
Competitors and Market Share
Key Competitors
- BDX
- DHR
- TMO
Competitive Landscape
Cytek has an edge in spectral flow cytometry technology but faces tough competition from companies with more resources and established market presence.
Major Acquisitions
Immudex ApS
- Year: 2021
- Acquisition Price (USD millions): 176
- Strategic Rationale: Expanded Cytek's reagent portfolio and enhanced capabilities in immune monitoring. Provides specialized reagents for assessing T-cell mediated immune responses.
Growth Trajectory and Initiatives
Historical Growth: Cytek Biosciences has experienced rapid growth in recent years driven by increased adoption of FSP technology.
Future Projections: Analyst projections are needed. Consider market trends, product pipeline, and competitive landscape for future growth projections.
Recent Initiatives: Recent initiatives include expanding reagent portfolio and increasing manufacturing capacity.
Summary
Cytek Biosciences is a growing player in the flow cytometry market, particularly with its innovative full spectrum profiling technology. Its strengths lie in its unique instrumentation and growing reagent portfolio. However, it faces competition from larger, well-established players. To continue its growth trajectory, Cytek needs to strategically expand its market reach and solidify its position in key application areas.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
DHR
Danaher Corporation
DHR
Danaher Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
WAT
Waters Corporation
WAT
Waters Corporation
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. The AI-based rating is a subjective assessment based on available data and may not reflect all factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 648 | Website https://cytekbio.com |
Full time employees 648 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.